Baseline Characteristics, Blood Pressures, and Laboratory Values

Slides:



Advertisements
Similar presentations
Reversing Atherosclerosis with Aggressive Lipid Lowering Reversing Atherosclerosis with Aggressive Lipid Lowering Presented at American Heart Association.
Advertisements

Rational, Trial Design, and Results of the ADAGIO Delayed Start Trial C. Warren Olanow, MD, FRCPC Henry P. and Georgette Goldschmidt Professor Chairman.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Clinical Trial Results. org Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis Stephen J. Nicholls, MBBS, PhD; E.
* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.
ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.
BackgroundBackground HDL-C levels are inversely related to CV event rates. HDL-C levels are inversely related to CV event rates. Torcetrapib, a cholesteryl.
Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results SJ Nicholls,
The TRial Of Preventing HYpertension (TROPHY) TROPHY.
SATURN: Objective To compare the effects of rosuvastatin 40 mg versus atorvastatin 80 mg on progression of coronary atherosclerosis assessed by intravascular.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.
Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.
Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:
Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.
Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:
Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.
Slide Source: Lipids Online Slide Library Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Nissen SE et al. JAMA.
Clinical Trial Results. org ILLUSTRATE Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Steven E.
Mega JL, et al. N Engl J Med 2009;360: Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.
Copyleft Clinical Trial Results. You Must Redistribute Slides ASTEROID Trial A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived.
The SPRINT Research Group
The American College of Cardiology Presented by Dr. Steven E. Nissen
Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.
Baseline Characteristics of the Patients Part I
Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.
The American Heart Association Presented by Dr. Steven E. Nissen
Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p
Oxford Niacin Trial.
TNT: Baseline and final LDL cholesterol levels
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.
GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.
Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.
TNT Study: Baseline Characteristics of the Patients
Management of hypertension in patients with chronic kidney disease
Trial profile John A Dormandy et al. Lancet 2005;366:
Study Design Ketil Lunde, et al. N Engl J Med 2006;355:
Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.
Fellström BC, et al. N Engl J Med 2009;360:1455-7
Description of studies for pooled analyses
Hypertension management in high risk type II diabetes with CKD: Insights from recent trials with a focus on albuminuria. A case based discussion  Matthew.
Baseline characteristics of CACTI type 1 diabetic subjects with cystatin C measurements (n=509), stratified by CAC progression status Maahs DM et al.
Enrollment and Outcomes
Stephen J. Nicholls, MBBS, PhD; E
Clinical Characteristics and Atheroma Burden of Subjects at Baseline Stratified According to Gender Nicholls SJ. et al. J Am Coll Cardiol 2007;49:
Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.
Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,
Baseline Characteristics of the Subjects
Flow of Patients Through the Trial
Trial profile Luc F Van Gaal, Lancet 2005;365:1389.
Flow of Patients Through Trial
Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:
Baseline Characteristics of the Subjects*
Patient Disposition James A. de Lemos et al. JAMA 2004; 292:
Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:
Disposition of Patients in the Atherogenic Dyslipidemia Study
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,
Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.
Demographic and Clinical Characteristics (means ± SD or %) of Subjects in Different Office SBP and DBP Categories Mancia G et al Hypertension. 2005;45:1072.
Baseline Characteristics of the Patients – Part I
RECORD Study: Enrollment and Outcomes
The ACCORD Study Group. NEJM 2010; Epub March 14
Characteristics of included studies
PROSPER: trial design                                                                                                                                                                 
Enrollment and Outcomes
Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.
Flow of study participants
Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.
Presentation transcript:

Baseline Characteristics, Blood Pressures, and Laboratory Values Baseline Characteristics, Blood Pressures, and Laboratory Values* - Part I Steven E. Nissen, et al. N Engl J Med 2007;356:1304-16

Baseline Characteristics, Blood Pressures, and Laboratory Values Baseline Characteristics, Blood Pressures, and Laboratory Values* - Part II Steven E. Nissen, et al. N Engl J Med 2007;356:1304-16

Primary and Secondary Study End Points as Evaluated on Intravascular Ultrasonography at Baseline and at 24-Month Follow-up with Changes from Baseline Steven E. Nissen, et al. N Engl J Med 2007;356:1304-16

Adverse Events, Clinical End Points, and Reasons for Discontinuation* Steven E. Nissen, et al. N Engl J Med 2007;356:1304-16

Changes in Systolic Blood Pressure in the Two Study Groups Steven E. Nissen, et al. N Engl J Med 2007;356:1304-16

Relationship between the Change in Percent Atheroma Volume and LDL Cholesterol in Regression-Progression Trials Using Intravascular Ultrasonography Steven E. Nissen, et al. N Engl J Med 2007;356:1304-16

Schematic Representation of the Metabolism of HDL Cholesterol Steven E. Nissen, et al. N Engl J Med 2007;356:1304-16